Dr. Lawrence May Joins Targeted Medical Pharma as Medical Director

Targeted Medical Pharma Inc.

Los Angeles, CA, April 23, 2019 — Targeted Medical Pharma Inc. (OTC:TRGM), an international biotechnology company and innovator in the development and distribution of scientifically based medical foods and dietary supplements announced the appointment of Lawrence May, M.D., F.A.C.P., as Medical Director.

“Dr. May brings extensive clinical, scientific and business experience developed over a thirty five year career in private practice and leadership roles in both public and private companies.” said Marcus Charuvastra, Managing Director of Targeted Medical Pharma. “Dr. May has played an integral role in the development and research of many of our medical food and dietary supplement products. He has extensive clinical experience educating and validating the clinical benefits of medical nutrition with his patients.”

Dr. May earned his M.D. from Harvard Medical School (’74) and has practiced primary care internal medicine integrating nutrition and lifestyle into the care of patients. Dr. May previously served as Chairman of the Medical Advisory Board and Executive Vice President for Medical and Scientific affairs at Herbalife International. Dr. May has appeared as an expert on numerous television and radio shows. He has consulted for law firms, pharmaceutical and biotech companies. He has worked for government agencies and nonprofits, including the Cancer Prevention Society, Los Angeles Free Clinic and the California Board of Medical Quality Assurance (BMQA). Dr. May has formulated outstanding dietary supplements offered in physician offices and successful infomercials. For over thirty years he has been on the full time clinical faculty of UCLA Geffen School of Medicine.

Dr. May earned his undergraduate degree Magna Cum Laude in Economics from Harvard College (’70) where he was elected to Phi Beta Kappa.  

“I am excited to rejoin Targeted Medical Pharma to advance the company’s mission to integrate efficacious supplements into patient care,” said Dr. May. “I am committed to educating healthcare providers and patients about safer, effective approaches for pain, anxiety, sleep and mood disorders. Collaborating with clinicians, scientists and regulators, Targeted Medical Pharma will improve the quality of life of an expanding population, particularly senior citizens, the most vulnerable to the side effects of pharmaceuticals.”

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based international biotechnology company that develops medical foods for the dietary management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. 

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Targeted Medical Pharma Forms Distribution Partnership with Cannabinoid Genetic Research Firm, ENDOCANNA Health

Los Angeles, February 6,  2019 – Targeted Medical Pharma (OTC: TRGM), today announced the completion of a distribution agreement with ENDOCANNA Health, a company that specializes in  personalized cannabis through a comprehensive Cannabinoid DNA Variant Test™.  

The Agreement is the first step in a multiyear partnership to improve personalized medicine by connecting clinical nutrition and the DNA variants that influence the endocannabinoid system to create effective and safer therapies for the long term management of chronic disease.  

Under the terms of the Agreement, ENDOCANNA Health has a three year nonexclusive right to the domestic distribution of the Company’s line of patented medical food products to include in their DNA Variant Testing program which is currently offered Nationwide by physicians and retailers.

“This partnership provides new opportunities for the research and development of novel therapies and clinical protocols capable of improving cannabinoid therapies for people suffering with chronic pain, anxiety, sleep disorders and obesity,” said Marcus Charuvastra, Managing Director of Targeted Medical Pharma. “Medical foods and phytocannabinoid therapies when used appropriately can have a very positive impact on nervous and endocannabinoid system health, restoring balance to systems that are degraded by disease, toxins, stress and genetics.”   

“Our partnership provides a unique opportunity to offer adjunct therapies that target multiple endogenous pathways simultaneously,” said Len May, CEO and co-founder of Endocanna Health. “By using Endocanna Health’s proprietary DNA report, we provide genetically-aligned protocols for clinicians to offer their patients along with analytical tools for clinical trials.” 

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the dietary management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. 

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

####

Targeted Medical Pharma Files SEC Form 15

Los Angeles – October 19, 2018 –  Targeted Medical Pharma a United States based medical nutrition and dietary supplement manufacturer, filed a Form 15 with the Securities and Exchange Commission. “After a detailed analysis and thoughtful deliberation of the advantages and disadvantages of being an SEC reporting company, the company’s board of directors and management concluded that the costs of reporting are too high and unreasonably burdensome on a company that is restructuring and rebuilding,” said interim Managing Director, Marcus Charuvastra. 

According to Mr. Charuvastra, “The preparation and filing of reports, retention of outside legal and accounting resources, in addition to the amount of management time spent on the documents along with the current volume of trading common stock do not justify being a SEC reporting company.” 

The Company will continue to file reports as required for trading common stock on the Pink Sheets. Questions regarding the company and common stock can be directed to info@tmedpharma.com.    

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. (TRGM) a publicly traded, United States based medical nutrition company that develops amino acid based medical foods and other oral nutrition products for the long term management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep, respiratory disorders, allergies and cognitive disorders.

The Company manufactures 8 proprietary amino acid based medical foods along with the dietary supplements Grotrexa (Japan), AppTrim (Japan), Hypertensa Advanced and Clearwayz. Each product uses Targeted Cellular Technology, the Company’s patented micro-nutrient delivery system that improves the absorption and cellular utilization of amino acids, nutrients and neurotransmitters. The products are manufactured in the United States and sold directly to physicians, pharmacies and patients in the United States, Japan, New Zealand, Ukraine, Russia and China.

Forward Looking Statement 

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

####